Platform Start-Up Anaphore And Mitsubishi Tanabe Ink Deal For Autoimmune Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Anaphore's novel Atrimer platform creates trivalent protein drugs to bind all three domains on trivalent ligands and receptors, a presumed advantage over two-armed antibodies.